SAN JOSE, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) of its next-generation Tablo platform, designed to deliver enterprise-level security, reliability and connectivity for hospitals, health systems and home providers of dialysis. With the clearance, Tablo ...

Majority investment in Project Jupiter, 2,000 MWh energy storage and up to 150 MWp solar in Germany Project backed by up to 500 MW secured grid connection, Ready to Build targeted for late 2026 Investment alongside Prime Capital includes substantial co-investment rights in additional European projects TEL AVIV, Israel, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Enlight Renewable Energy (TASE & NASDAQ: ENLT), a leading global renewable energy developer and an independent power producer, has signed an agreement to acq ...

Milestone highlights LPL’s enduring commitment to financial planning innovation and leadershipSAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- LPL Financial LLC, a leading wealth management firm, today announced that 6,200 LPL-affiliated financial advisors have earned the CERTIFIED FINANCIAL PLANNER™ (CFP®) designation as of December 31, 2025 — the most of any firm in the industry. This achievement reflects LPL’s continued investment in the technology, services and infrastructure that define the modern advisor ...

Scalable, Engagement-Driven Partnership Positioned to Deliver Material Revenue Uplift and Accelerate Annual GrowthSINGAPORE, Jan. 27, 2026 (GLOBE NEWSWIRE) -- FAST TRACK GROUP (NASDAQ: FTRK) ("Fast Track" or the "Company"), a leading entertainment-focused event management and celebrity agency company, announced that Fast Track Entertainment (“FTE”) has signed a Memorandum of Understanding (MoU) with South Korean entertainment agency Leanbranding to support the global growth of rising K-pop girl group KIIRAS ...

SANTA ROSA, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Summit State Bank (the “Bank”) (Nasdaq: SSBI) today reported net income of $1,067,000, or $0.16 per diluted share for the fourth quarter ended December 31, 2025, compared to net loss of $7,142,000, or $1.06 loss per diluted share for the fourth quarter ended December 31, 2024. For the year ended December 31, 2025, the Bank reported net income of $6,796,000, or $1.01 per diluted share compared to a net loss of $4,193,000, or $0.62 loss per diluted share f ...

Presentation Outlines Executive Leadership, AVAX Treasury Strategy, and Fintech M&A Framework WEST PALM BEACH, FL, Jan. 27, 2026 (GLOBE NEWSWIRE) -- AVAX One Technology Ltd. (Nasdaq: AVX) (“AVAX One” or the “Company”), today highlighted its institutional onchain finance strategy and operating playbook in its new investor presentation, now available on ir.avax-one.com. The investor presentation outlines AVAX One’s strategy to build a regulated, institutional gateway to the onchain financial economy powered b ...

Core Viewpoint - Foresight Autonomous Holdings Ltd. is advancing its collaboration with SoftBank Corp. to validate Eye-Net's V2X collision prediction and prevention technology, aiming to enhance road safety and operational efficiency through real-time location information exchange among road users [1][2][3] Group 1: Collaboration Details - The collaboration builds on positive results from a previous proof-of-concept project with SoftBank, focusing on tailoring the solution to meet SoftBank's specific needs and evaluating its potential for new market introductions [2] - The initiative emphasizes a shared commitment to accelerating the deployment of connected mobility solutions, which is expected to improve situational awareness and reduce traffic-related incidents in Japan and beyond [3] Group 2: Company Overview - Eye-Net develops next-generation V2X collision prevention solutions and smart automotive systems aimed at enhancing road safety and situational awareness for all road users in urban environments, utilizing advanced AI technology and existing cellular networks for real-time pre-collision alerts [4] - Foresight Autonomous Holdings Ltd. is a technology company focused on developing advanced 3D perception and cellular-based applications through its subsidiaries, including Eye-Net Mobile Ltd., which specializes in both "in-line-of-sight" and "beyond-line-of-sight" accident-prevention solutions [6][7]

Geneva, Switzerland, Jan. 27, 2026 (GLOBE NEWSWIRE) -- SEALSQ Corp (NASDAQ: LAES) ("SEALSQ" or "Company"), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software products, today announced that it is redefining vertical integration in the quantum era by building a platform where trust begins, in silicon. Rather than developing quantum solutions in isolated layers of hardware, software, or connectivity, SEALSQ has designed a fully integrated arc ...

Precise MRD™ to transition from research-use-only into a limited clinical launch in March 2026SALT LAKE CITY, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced a commercialization roadmap for its Precise MRD™ (molecular residual disease) assay and highlighted compelling data that reinforces the clinical value of ultrasensitive circulating tumor DNA (ctDNA) detection across cancer types. Myriad will launch ...

Core Insights - Ernexa Therapeutics has been selected as one of ten companies globally to participate in the Japan Entry Acceleration Program (JEAP), highlighting its innovative cell therapy platform for advanced cancer and autoimmune diseases [1][2]. Group 1: Company Overview - Ernexa Therapeutics focuses on developing novel cell therapies, particularly using induced pluripotent stem cells (iPSCs) to create allogeneic synthetic induced mesenchymal stem cells (iMSCs), which provide scalable treatment solutions [7]. - The company’s lead products include ERNA-101, aimed at enhancing the immune system's ability to target tumors, and ERNA-201, which addresses harmful inflammation in autoimmune diseases [5][8]. Group 2: Program Participation - JEAP is a competitive initiative by the Japan External Trade Organization (JETRO), attracting around 70 companies from 25 countries, emphasizing the high level of competition [2][6]. - Participation in JEAP offers Ernexa access to expert mentoring, market-entry guidance, and opportunities for collaboration with leading Japanese research and development organizations [4][6]. Group 3: Strategic Goals - The program is expected to advance Ernexa's pipeline in Japan, with ERNA-101 entering first-in-human clinical trials for ovarian cancer this year, addressing significant unmet needs in cancer treatment [5]. - The company aims to leverage JEAP to explore strategic partnerships and clinical development opportunities, ultimately striving to deliver hope to patients with serious conditions [3].